We are actively seeking strategic partners that align with our vision. We are interested in partnering worldwide rights to the following pre-commercial asset:
- A-101 45% Topical Solution, our investigational drug candidate for common warts.
We are actively seeking research and licensing partners to fully leverage the transformational potential of our KINect® platform for drug discovery. Specific areas of interest include:
- Kinases inhibitors for autoimmune diseases, such as rheumatoid arthritis, chronic inflammation disease (e.g. inflammatory bowel disease), autoinflammatory diseases (e.g. CAPS, Stills Disease), and cancer.
- New therapeutic applications for our cysteinome-targeted chemical library representing 60% of the kinome.